{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:39:41Z","timestamp":1792269581703,"version":"4.4.0"},"reference-count":32,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"abstract":"\n Importance<\/jats:title>\n Migraine affects individuals of reproductive age, but treatment options during pregnancy are limited due to safety concerns. Anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) are effective for migraine prevention; however, CGRP is important in placental development.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether early pregnancy exposure to anti-CGRP mAbs or propranolol is associated with spontaneous abortion compared with no exposure.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study used data from the AM-PREGNANT cohort, derived from the Merative MarketScan Commercial Database, from 2018 to 2021. Participants were followed up through 20 weeks\u2019 gestation or until spontaneous abortion or censoring. Among 7\u202f991\u202f200 pregnancies identified in the AM-PREGNANT cohort, 7119 individuals contributing 7579 singleton pregnancies met the predefined eligibility criteria, including age 15 to 45 years, continuous insurance enrollment, last menstrual period (LMP) on or after November 1, 2018, pregnancy end or 20-week censoring by December 31, 2021, and pregestational migraine, defined as a migraine diagnosis or triptan or ergot prescription within 6 months before LMP. Data were analyzed in early 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Anti-CGRP mAbs (erenumab, fremanezumab, galcanezumab, eptinezumab) or propranolol, defined as 1 or more filled prescription or injection procedure claim during follow-up and modeled as time-varying.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n Spontaneous abortion occurring at 20 weeks\u2019 or less gestation. Multivariable Cox proportional hazards models adjusted for comorbidities and concomitant medications estimated the risk of spontaneous abortion.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 7579 pregnancies in 7119 individuals (mean [SD] age, 31.6 [5.5] years), 1862 spontaneous abortions occurred. There were 100 spontaneous abortions (28.6%) during anti-CGRP mAb-exposed person-time, compared with 37 events among propranolol-exposed person-time without anti-CGRP mAbs (12.8%). Compared with unexposed individuals, anti-CGRP mAbs exposure was associated with an increased risk of spontaneous abortion (adjusted hazard ratio [aHR], 1.42; 95% CI, 1.12-1.80), which remained similar in bias-adjusted analyses (HR, 1.33; 95% simulation interval [SI], 1.23-1.45). Propranolol exposure was not associated with increased risk (aHR, 1.02; 95% CI, 0.71-1.47; bias-adjusted HR, 1.00; 95% SI, 0.96-1.03).<\/jats:p>\n <\/jats:sec>\n \n Conclusion and Relevance<\/jats:title>\n In this study, early pregnancy exposure to anti-CGRP mAb was associated with a higher risk of spontaneous abortion, while no association was observed with propranolol. These findings support further evaluation of anti-CGRP mAb safety and emphasize counseling for individuals of childbearing potential.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2026.3573","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:30:30Z","timestamp":1791819030000},"source":"Crossref","is-referenced-by-count":1,"title":["Early Pregnancy Use of Anti-CGRP Monoclonal Antibodies and Propranolol and Spontaneous Abortion Risk"],"prefix":"10.1001","author":[{"given":"Leah K.","family":"Flatman","sequence":"first","affiliation":[{"name":"Centre de Recherche Azrieli, Centre Hospitalier Universitaire Sainte-Justine, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Faculty of Pharmacy, University of Montreal, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisiane F.","family":"Leal","sequence":"additional","affiliation":[{"name":"Centre de Recherche Azrieli, Centre Hospitalier Universitaire Sainte-Justine, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Leroux","sequence":"additional","affiliation":[{"name":"Montreal Neurological Clinic, McGill Neurology Department, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[{"name":"Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, Bronx, New York"},{"name":"Montefiore Headache Center, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anick","family":"B\u00e9rard","sequence":"additional","affiliation":[{"name":"Centre de Recherche Azrieli, Centre Hospitalier Universitaire Sainte-Justine, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Faculty of Pharmacy, University of Montreal, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Faculty of Medicine, Universit\u00e9 Claude Bernard Lyon 1, Lyon, France"},{"name":"Faculty of Medicine, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"5","key":"noi260066r1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/head.14709","article-title":"Prevalence and burden of migraine in the United States: a systematic review.","volume":"64","author":"Cohen","year":"2024","journal-title":"Headache"},{"issue":"1","key":"noi260066r2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","article-title":"Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019.","volume":"21","author":"Steiner","year":"2020","journal-title":"J Headache Pain"},{"key":"noi260066r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104943","article-title":"Resistant and refractory migraine: clinical presentation, pathophysiology, and management.","volume":"99","author":"Ornello","year":"2024","journal-title":"EBioMedicine"},{"issue":"4","key":"noi260066r4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","article-title":"Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update.","volume":"64","author":"Charles","year":"2024","journal-title":"Headache"},{"issue":"1","key":"noi260066r5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20142022 update.","volume":"23","author":"Sacco","year":"2022","journal-title":"J Headache Pain"},{"key":"noi260066r6","doi-asserted-by":"publisher","DOI":"10.1111\/head.15027","article-title":"The state of insurance coverage of calcitonin gene-related peptide-targeted medications and its impact on the implementation of the American Headache Society\u2019s 2024 consensus statement: an interrupted time-series analysis.","author":"Moskatel","year":"2026","journal-title":"Headache"},{"issue":"1","key":"noi260066r7","doi-asserted-by":"publisher","first-page":"H230","DOI":"10.1152\/ajpheart.00140.2003","article-title":"Involvement of calcitonin gene-related peptide in control of human fetoplacental vascular tone.","volume":"286","author":"Dong","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"noi260066r8","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1095\/biolreprod67.2.624","article-title":"Infusion of pregnant rats with calcitonin gene-related peptide (CGRP)(8-37), a CGRP receptor antagonist, increases blood pressure and fetal mortality and decreases fetal growth.","volume":"67","author":"Gangula","year":"2002","journal-title":"Biol Reprod"},{"issue":"5","key":"noi260066r9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2174\/1570161111311050007","article-title":"Calcitonin gene-related family peptides in vascular adaptations, uteroplacental circulation, and fetal growth.","volume":"11","author":"Yallampalli","year":"2013","journal-title":"Curr Vasc Pharmacol"},{"issue":"5","key":"noi260066r10","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1097\/AOG.0000000000004766","article-title":"Headaches in pregnancy and postpartum: ACOG Clinical Practice Guideline No. 3.","volume":"139","author":"American College of Obstetricians and Gynecologists","year":"2022","journal-title":"Obstet Gynecol"},{"issue":"3","key":"noi260066r11","first-page":"1","article-title":"Updated Canadian Headache Society migraine prevention guideline with systematic review and meta-analysis.","volume":"52","author":"Medrea","year":"2024","journal-title":"Can J Neurol Sci"},{"issue":"11","key":"noi260066r12","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251393945","article-title":"Migraine management during pregnancy, breastfeeding and in women planning pregnancy.","volume":"45","author":"Ornello","year":"2025","journal-title":"Cephalalgia"},{"issue":"4","key":"noi260066r13","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231158083","article-title":"Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase\u00ae.","volume":"43","author":"Noseda","year":"2023","journal-title":"Cephalalgia"},{"issue":"1","key":"noi260066r14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s10194-022-01533-6","article-title":"Pre-pregnancy migraine diagnosis, medication use, and spontaneous abortion: a prospective cohort study.","volume":"23","author":"Crowe","year":"2022","journal-title":"J Headache Pain"},{"key":"noi260066r15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1608403","article-title":"The American Pregnancy Mother-Child Cohort: description and prevalence of baseline outcomes and medication dispensing.","volume":"16","author":"Leal","year":"2025","journal-title":"Front Pharmacol"},{"issue":"5","key":"noi260066r17","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/head.13275","article-title":"Direct and indirect healthcare resource utilization and costs among migraine patients in the United States.","volume":"58","author":"Bonafede","year":"2018","journal-title":"Headache"},{"issue":"4","key":"noi260066r19","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/pds.5574","article-title":"Validation of claims-based algorithms to identify non-live birth outcomes.","volume":"32","author":"Zhu","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"noi260066r20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40264-022-01261-5","article-title":"Development and validation of ICD-10-CM-based algorithms for date of last menstrual period, pregnancy outcomes, and infant outcomes.","volume":"46","author":"Chomistek","year":"2023","journal-title":"Drug Saf"},{"issue":"1","key":"noi260066r22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jclinepi.2009.03.012","article-title":"Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomes.","volume":"63","author":"Austin","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"noi260066r24","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1212\/01.wnl.0000323925.29520.e7","article-title":"Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment.","volume":"71","author":"Bigal","year":"2008","journal-title":"Neurology"},{"key":"noi260066r25","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/PPA.S346660","article-title":"Treatment patterns for calcitonin gene-related peptide monoclonal antibodies including galcanezumab versus conventional preventive treatments for migraine: a retrospective US claims study.","volume":"16","author":"Varnado","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"noi260066r26","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.yrtph.2019.05.013","article-title":"Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine.","volume":"106","author":"Bussiere","year":"2019","journal-title":"Regul Toxicol Pharmacol"},{"issue":"2","key":"noi260066r27","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1212\/WNL.54.2.308","article-title":"Headache and major depression: is the association specific to migraine?","volume":"54","author":"Breslau","year":"2000","journal-title":"Neurology"},{"issue":"5","key":"noi260066r28","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.fertnstert.2023.08.954","article-title":"The prevalence of sporadic and recurrent pregnancy loss.","volume":"120","author":"Genovese","year":"2023","journal-title":"Fertil Steril"},{"issue":"6","key":"noi260066r29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/bdra.23014","article-title":"A systematic review to calculate background miscarriage rates using life table analysis.","volume":"94","author":"Ammon Avalos","year":"2012","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"2","key":"noi260066r30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.contraception.2017.05.010","article-title":"Examining intendedness among pregnancies ending in spontaneous abortion.","volume":"96","author":"Flink-Bochacki","year":"2017","journal-title":"Contraception"},{"issue":"3","key":"noi260066r31","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1526-4610.2006.00631.x","article-title":"Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study.","volume":"47","author":"Diamond","year":"2007","journal-title":"Headache"},{"issue":"5","key":"noi260066r32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/EDE.0000000000001890","article-title":"Use of health administrative data to identify migraine in individuals with a recognized pregnancy: a validation study in Ontario, Canada.","volume":"36","author":"Albanese","year":"2025","journal-title":"Epidemiology"},{"key":"noi260066r18","first-page":"62","volume-title":"Basic & Clinical Pharmacology","author":"Holford","year":"2021","edition":"15th ed"},{"key":"noi260066r21","volume-title":"Health-Care Utilizations as Proxies for Listing-Level Severity","author":"National Academies of Sciences, Engineering, and Medicine","year":"2018"},{"key":"noi260066r23","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-87959-8","volume-title":"Applying quantitative bias analysis to epidemiologic data","author":"Lash","year":"2009"},{"key":"noi260066r16","unstructured":"Merative. Merative MarketScan research databases. Accessed September 11, 2026. https:\/\/www.merative.com\/documents\/merative-marketscan-research-databases"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2854982\/jamaneurology_flatman_2026_oi_260066_1790869912.2633.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:30:33Z","timestamp":1791819033000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2854982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":32,"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2026.3573","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,12]]}}}